Lisuride Pharmacology and Treatment of Parkinson’s Disease

  • G. Gopinathan
  • R. Horowski
  • I. H. Suchy
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 88)

Abstract

Lisuride hydrogen maleate [1,1 diethyl-3-(9,10-didehydro-6-methyl-8α-ergolinyl] urea is the first derivative of isolysergic acid in clinical use. It is an 8-α-aminoergoline and was synthesized by Zikan and Semonsky (1968). It is a white slightly bitter tasting substance, which is reasonably stable at room temperature if not exposed to light. Lisuride hydrogen maleate is soluble in water or saline up to 1 mg/ml. Owing to its low effective dose, it is therefore the first dopamine agonist which can also be used on a parenteral basis (Dorow et al. 1980).

Keywords

Serotonin Neurol Clonidine Cote Prazosin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adams LM, Geyer MA (1985) Patterns of exploration in rats distinguishes lisuride from lysergic acid diethylamide. Pharmacol Biochem Behav 23: 461–468PubMedCrossRefGoogle Scholar
  2. Agnoli A, Ruggieri S, Baldassarre M, Stocchi F, Denaro A, Falaschi P (1983) Dopaminergic ergots in Parkinsonism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds). Lisuride and other dopamine agonists. Raven, New York, pp 407–417Google Scholar
  3. Ahlenius S, Larsson K, Svensson L (1980) Stimulating effects of lisuride on masculine sexual behaviour. Eur J Pharmacol 64: 47–51PubMedCrossRefGoogle Scholar
  4. Aizawa T, Kutsuzawa T, Otomo E, Goto F, Tazaki Y, Abe H, Omae T, Kameyama M, Ito H (1980) Clinical utility of eunal in treatment of cerberovascular disorders: multi-center double-blind study in comparison with dihydroergotoxine mesylate. Clin Eval 8: 577–628Google Scholar
  5. Albizzati MG, Alemani A, Bassi G, Ferrarese C, Frattola L, Trabucchi M (1982) Effetti del lisuride nella patologia discinetico distonica: Considerazioni patogenetiche. In: Agnoli A, Bertolani G (eds) Morbo di Parkinson e compromissione delle attivita’ nervose superiori. 8th Meeting LIMPE, Rome, 31 Oct 1981. Guanelli, Rome, pp 223–231Google Scholar
  6. Azuma H, Oshino N (1980) Stimulatory action of lisuride on dopamine-sensitive adenylate cyclase in the rat striatal homogenate. Jpn J Pharmacol 30: 629–639PubMedCrossRefGoogle Scholar
  7. Azuma H, Miyazawa T, Ishikawa T, Oshino N (1982) Effects of an ergot derivative lisuride, on the central nervous system. Stimulatory effect on local cerebral glucose utilization in the rat Folia Pharmacol Jpn 80: 69–81Google Scholar
  8. Battaglia G, Titeler M (1981) Direct binding of [3H] lisuride to adrenergic and serotonergic receptors. Life Sci 29: 909–916PubMedCrossRefGoogle Scholar
  9. Bergstrom DA, Bromley SD, Walters JR (1984) Dopamine agonists increase pallidal unit activity: attenuation by agonist pretreatment and anesthesia. Eur J Pharmacol 100: 3–12PubMedCrossRefGoogle Scholar
  10. Besser GM, Wass JAH, Grossmann A, Moult PJA, Bouloux P (1983) Hormonal and clinical effects of dopamine agonists In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 239–254Google Scholar
  11. Birkmayer W, Riederer P (1983) Effects of lisuride on motor function, psychomotor activity, and psychic bahaviour in Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 453–461Google Scholar
  12. Bittkau S, Przuntek H (1986) Psychosis and the lisuride pump. Lancet 11:349 (letter)Google Scholar
  13. Bohnet HG, Hanker JP, Horowski R, Wickings EJ, Schneider HPG (1979) Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders. Acta Endocrinol. 92: 8–19PubMedGoogle Scholar
  14. Bohnet HG, Hilland U, Hanker JP, Schneider HPG (1981) Hormonelle Diagnostik und Therapie der Mastodynie. Wissenschaftl Information 7: 87–94Google Scholar
  15. Bosio A, Bassi S, Govoni S, Spano PF, Trabucchi M, Covelli V, Frattola L (1984) Lisuride in extrapyramidal disorders: a possible mechanism of action. In: Hassler RG, Christ JF (eds) Advances in neurology vol 40. Raven, New York, pp 523–526Google Scholar
  16. Bracco F, Meneghetti G, Feria S, Giometto B, Battistin L (1984) Effetti della lisuride nel trattamento del morbo di Parkinson. Osservazioni preliminari. In: Agnoli A, Bertolani G (eds) LIMPE Atti della 10. Reunione,Disorderi autonomici e correlati neuroendocrini delle malattie extrapiramidali’. Guanella, Rome, pp 272–278Google Scholar
  17. Bräutigam M, Flosbach CW, Herken H (1980) Depression of reserpine-induced muscular rigidity in rats after administration of lisuride into the spinal subarachnoid space. Naunyn-Schmiedeberg’s Arch Pharmacol 315: 177–179CrossRefGoogle Scholar
  18. Brazenor RM, Angus JA (1982) Actions of serotonin antagonists on dog coronary artery. Eur J Pharmacol 81: 569–576PubMedCrossRefGoogle Scholar
  19. Brinkmann A, Schumm F, Dichgans J (1985) Therapie des Meige-Syndroms. In: Gänshirt H, Berlit P (eds) Kardiovaskuläre Erkrankungen und Nervensystem, Neu- rotoxikologie, Probleme des Hirntodes. Springer, Berlin Heidelberg New York, pp 662–665Google Scholar
  20. Burdman JA, Calabrese MT, Harcus CT, MacLeod RM (1982) Lisuride, a dopamine agonist, inhibits DNA synthesis in the pituitary gland. Neuroendocrinology 35: 282–286PubMedCrossRefGoogle Scholar
  21. Burns RS, Calne DB (1981) Treatment of parkinsonism with artificial dopaminomimetics; pharmacokinetic considerations. In: Corsini GU, Gessa GL (eds) Apomorphine and other dopaminomimetics, vol 2. Raven, New York, pp 93–106Google Scholar
  22. Burns, RS, Gopinathan G, Hümpel M, Dorow R, Calne DB (1984) Disposition of oral lisuride in Parkinson’s disease. Clin Pharmacol Ther 35: 548–556PubMedCrossRefGoogle Scholar
  23. Camerlingo M, Bottacchi E, D’Alessandro G, Gambaro P, Crippa D, Finelli F, Mamoli A (1986) Un anno di esperienza con ergot-derivati nel trattamento di monoterapia di pazienti Parkinsoniani di prima diagnosi. In: Agnoli A, Battistin L (eds) L.I.M.P.E., Atti della 12. Riunione,Morbo di Parkinson: le nuove terapie’. Guanella, Rome, 1986, pp 188–196Google Scholar
  24. Cangi F, Fanciullacci M, Pietrini U, Boccuni M, Sicuteri F (1985) Emergence of pain and extra-pain phenomena from dopaminomimetics in migraine. In: Pfaffenrath V, Lundberg PO, Sjaastad O (eds) Updating in headache. Springer, Berlin Heidelberg New York, pp 276–280Google Scholar
  25. Caraceni T, Giovannini P, Parati E, Scigliano G, Grassi MP, Carella F (1984) Bromocriptine and lisuride in Parkinson’s disease. In: Hassler RG, Christ JF (eds) Advances in neurology, vol 40. Raven, New York, pp 531–535Google Scholar
  26. Carruba MO, Mantegazza P (1983) Behavioural pharmacology of ergot derivatives. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 65–77Google Scholar
  27. Carruba MO, Ricciardi S, Negreanu J, Calogero M, Mantegazza P (1980) Effects of lisuride on body temperature of rats and rabbits: relation to microsomal biotransformation and dopaminergic receptor stimulation. Psychopharmacology 70: 223–229PubMedCrossRefGoogle Scholar
  28. Carruba MO, Ferrari P, Rossi AC, Mantegazza P (1983) Effects of antihypertensive drugs on sexual behaviour of male rats. Pharmacol Res Commun 15: 367–375PubMedCrossRefGoogle Scholar
  29. Carruba MO, Ricciardi S, Chiesara E, Spano PF, Mantegazza P (1985) Tolerance to some behavioural effects of lisuride, a dopamine receptor agonist, and reverse tolerance to others, after repeated administration. Neuropharmacology 24: 199–206PubMedCrossRefGoogle Scholar
  30. Carstensen M, Söhnchen R, Braendle W, Bettendorf G (1983) Effects of prolactin-lowering agents in the treatment of disorders of fertility. In: Calne DB, Harowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 337–343Google Scholar
  31. Carvey PM, Klawans HL (1983) Effect of chronic lisuride treatment on stereotypical and myoclonic jumping behavior in guinea pigs. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 97–107Google Scholar
  32. Chiodini PG, Liuzzi A, Silvestrini F, Verde G, Cozzi R, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1978) Size reduction of a prolactin secreting adenoma during a long-term treatment with a dopamine-agonist: (lisuride). Int Symp on Pituitary Microadenomas, Milan (abstract )Google Scholar
  33. Chiodini PG, Liuzzi A, Verde G, Cozzi R, Silvestrini F, Marsili MT, Horowski R, Passerini F, Luccarelli G, Borghi PG (1980) Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Clin Endocrinol 12: 47–51CrossRefGoogle Scholar
  34. Chiodini P, Liuzzi A, Cozzi R, Verde G, Oppizzi G, Dallabonzana D, Spelta B, Silvestrini F, Borghi G, Luccarelli G, Rainer E, Horowski R (1981) Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J Clin Endocrinol Metab 53: 737–743PubMedCrossRefGoogle Scholar
  35. Cote T, Munemura M, Kebabian J (1979) Lisuride hydrogen maleate: an ergoline with beta-adrenergic antagonist activity. Eur J Pharmacol 59: 303–306PubMedCrossRefGoogle Scholar
  36. Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Tsuruta K, Brown EM, Kebabian JW (1983) Actions of lisuride on adrenoceptors and dopamine receptors. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 45–53Google Scholar
  37. Critchley P, Grandas Perez F, Quinn N, Coleman R, Parkes D, Marsden CD (1986) Psychosis and the lisuride pump. Lancet II:349 (letter)CrossRefGoogle Scholar
  38. Cronin MJ, Valdenegro CA, Perkins SN, MacLeod RM (1981) The 7315 a pituitary tumor is refractory to dopaminergic inhibition of prolactin release but contains dopamine receptors. Endocrinology 109: 2160–2166PubMedCrossRefGoogle Scholar
  39. Crosignani PG, Ferrari C, Liuzzi A, Benco R, Mattei A, Rampini P, Dellabonzana D, Scarduelli C, Spelta B (1982) Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline, and lisuride. Fertil Steril 37: 61–67PubMedGoogle Scholar
  40. Da Prada M, Bonetti EP, Keller HH (1977) Induction of mounting behaviour in female and male rats by lisuride. Neurosci Lett 6: 349–353PubMedCrossRefGoogle Scholar
  41. De Cecco L, Venturini PL, Ragni N, Valenzano M, Constantini S, Horowski R (1983) Dopaminergic ergots in lactation and cycle disturbances. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 291–299Google Scholar
  42. Delitala G, Wass JAH, Stubbs WA, Jones A, Williams S, Besser GM (1979) The effect of lisuride hydrogen maleate, an ergot derivative on anterior pituitary hormone secretion in man. Clin. Endocrinol 11: 1–9CrossRefGoogle Scholar
  43. Desaga U, Lüdecke D, Kühne D (1983) Prolactin lowering effect of lisuride and reduction of tumor size in patients with prolactinomas. Periodicum Biologorum 85, Suppl 1: 73–82Google Scholar
  44. Desaga U, Reich-Schulze E, Gräf K-J, Dorow R, Frahm H (1985) Endocrine effects of the dopamine agonist lisuride in patients with chronic renal failure on long-term hemodialysis. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin. Basic and clinical correlates. Liviana, Padova, pp 761–771Google Scholar
  45. Dorow R, Gräf K-J, Nieuweboer B, Horowski R (1980) Intravenous lisuride: a new tool for testing responsiveness to dopaminergic agonists and neuroendocrine function. Acta Endocrinol (Kbh) 94, Suppl 234: 9 (abstract)Google Scholar
  46. Dorow R, Breitkopf M, Desaga U, Ebeling J, Zimmermann R, Horowski R (1981) Pharmacokinetics and clinical effects of lisuride. Acta Endocrinol 97, Suppl 243: 413 (abstract)Google Scholar
  47. Dorow R, Breitkopf M, Gräf K-J, Horowski R (1983) Neuroendocrine effects of lisuride and its 9,10-dihydrogenated analog in healthy volunteers. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 161–174Google Scholar
  48. Fink H, Morgenstern R (1985) Locomotor effects of lisuride: a consequence of dopaminergic and serotonergic actions. Psychopharmacology 85: 464–468PubMedCrossRefGoogle Scholar
  49. Flosbach CW, Bräutigam M, Dreesen R, Herken H (1982) Action of lisuride on reserpine-induced muscular rigidity in rats after local application into the striatum, ventricular space or the spinal subarachnoid space. Arzneim Forsch Drug Res 32: 488–491Google Scholar
  50. Frattola L, Albizzati MG, Bassi S, Ferrarese C, Trabucchi M (1982) ‘On-Off’ phenomena, dyskinesias and dystonias. Acta Neurol Scand 66:227–236Google Scholar
  51. Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M (1983) Acute treatment of Huntington’s chorea with lisuride. J Neurol Sci 59: 247–253PubMedCrossRefGoogle Scholar
  52. Fujita N, Saito K, Yonehara N, Watanabe Y, Yoshida H (1979) Binding of [3H] lisuride hydrogen maleate to striatal membranes of rat brain. Life Sci 25: 969–974PubMedCrossRefGoogle Scholar
  53. Fuxe K, Fredholm BB, Ögren S-O, Agnati LF, Hökfelt T, Gustafsson J-A (1978) Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioural analysis. Fed Proc 37: 2181–2191PubMedGoogle Scholar
  54. Garattini S, Consolo S, Ladinski H (1980) Neuronal links in the CNS: focus on dopaminergic and serotonergic regulation of striatal cholinergic neurons. Pol J Pharmacol Pharm 32:155–164PubMedGoogle Scholar
  55. Gerber R, Barbaz BJ, Martin LL, Neale R, Williams M, Liebman JM (1985) Antagonism of L-5-hydroxytryptophan-induced head twitching in rats by lisuride: a mixed 5-hydroxytryptamine agonist-antagonist? Neurosci Lett 60: 207–213PubMedCrossRefGoogle Scholar
  56. Gessa GL (1988) Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27:201–210Google Scholar
  57. Giuliani L, Barreca T, Giberti C, Pescatore D, Magnani G, Martorana G, Bottaro L, Damonte P, Rolandi E (1982) Clinical effects of a prolactin-inhibiting drug, lisuride, in patients with benign prostatic hypertrophy. Curr Ther Res 32: 8–16Google Scholar
  58. Glusa E, Markwardt F (1984) Mechanism of metallic mercury oxidation in vitro by catalase and peroxidase. Biochem Pharmacol 33: 490–493CrossRefGoogle Scholar
  59. Glusa E, Markwardt F, Barthel W (1979) Studies on the inhibition of adrenaline-induced aggregation of blood platelets. Pharmacology 19: 196–201PubMedCrossRefGoogle Scholar
  60. Gopinathan G, Teravainen H, Dambrosia J, Ward C, Sanes J, Stuart W, Evarts E, Calne D (1980) Studies on parkinson disease II: evaluation of lisuride as a therapeutic agent. Annu Course of the American Academy of Neurology, 32nd Meeting, New Orleans (abstract)Google Scholar
  61. Gopinathan G, Teräväinen H, Dambrosia JM, Ward CD, Sanes JN, Stuart WK, Evarts EV, Calne DB (1981) Lisuride in parkinsonism. Neurology (NY) 31: 371–376Google Scholar
  62. Graf M, Pletscher A (1979) Shape change of blood platelets — a model for cerebral 5-hydroxytryptamine receptors? Br J Pharmacol 65: 601–608PubMedGoogle Scholar
  63. Gräf K-J, Neumann F, Horowski R (1976) Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98: 598–605PubMedCrossRefGoogle Scholar
  64. Gräf K-J, Horowski R, El Etreby MF (1977) Effect of prolactin inhibitory agents on the ectopic anterior pituitary and the mammary gland in rats. Acta Endocrinol. 85: 267–278PubMedGoogle Scholar
  65. Gräf K-J, Schmidt-Gollwitzer M, Horowski R, Dorow R (1982) Effect of metoclopramide and lisuride on hypophyseal and gonadal function in men. Clin Endocrinol 17: 243–251CrossRefGoogle Scholar
  66. Halbhübner K, Herken H, Loos D (1978) Experimental neuropathy with parkinsonlike muscular rigidity. Arzneim Forsch Drug Res 28: 1743–1752Google Scholar
  67. Hara K, Ikoma Y, Oshino N (1982 a) Effects of an ergot derivative, lisuride, on the central dopaminergic system — studies of behavioral pharmacology. Folia Pharmacol Jp 80: 1–13Google Scholar
  68. Hara K, Ikoma Y, Nakao H, Ezumi K, Oshino N, Shiota C, Sasagawa S (1982 b) Central dopaminergic function in stroke-prone spontaneously hypertensive rats (SHRSP): II. Effects of chronic treatment with lisuride on the impaired swimming ability. Folia Pharmacol Jp 80: 385–394Google Scholar
  69. Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 107: 487–506PubMedCrossRefGoogle Scholar
  70. Hardt W, Schmidt-Gollwitzer M, Horowski R (1979) Suppression of lactation with lisuride. Gynecol Obstet Invest 10: 95–105PubMedCrossRefGoogle Scholar
  71. Heinlein W, Stracke H, Schroder O, Laube H, Grothe E, Schatz H (1983) Dopaminagonistentherapie bei Hypophysentumoren. Therapiewoche 33: 6123–6128Google Scholar
  72. Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K (1977) Clinical effectiveness of lisuride hydrogen maleate: a double blind trial versus methysergide. Headache 17: 54–60PubMedCrossRefGoogle Scholar
  73. Herrmann WM, Kristof M, Sastre y Hernandez M (1978) Preventive treatment of migraine headache with a new isoergolenyl derivative. J Int Med Res 6: 476–482Google Scholar
  74. Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81: 595–601PubMedCrossRefGoogle Scholar
  75. Horowski R (1978) Differences in the dopaminergic effects of the ergot derivatives bromocriptine, lisuride and d-LSD as compared with apomorphine. Eur J Pharmacol 51: 157–166PubMedCrossRefGoogle Scholar
  76. Horowski R ( 1982 a) Role of monoaminergic mechanisms in the mechanism of action of ergot derivatives used in migraine. In: Rose FC (ed) Advances in migraine. Raven, New York, pp 187–198Google Scholar
  77. Horowski R (1982 b) Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine. Adv Neurol 33:325–334Google Scholar
  78. Horowski R (1983) Pharmacological effects of lisuride and their potential role in further research. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 127–139Google Scholar
  79. Horowski R (1986) Psychiatric side-effects of high-dose lisuride therapy in parkinsonism. Lancet II:510 (letter)CrossRefGoogle Scholar
  80. Horowski R, Dorow R (1981) Influence of estraciol and other gonadal steroids on central effects of lisuride and comparable ergot derivatives. In: Wuttke W, Horowski R (eds) Gonadal steroids and brain function. Springer, Berlin Heidelberg New York, pp 169–181Google Scholar
  81. Horowski R, Gräf K-J (1976) Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat. Neuroendocrinology 22: 273–286PubMedCrossRefGoogle Scholar
  82. Horowski R, McDonald RJ (1983) Experimental and clinical aspects of ergot derivatives used in the treatment of age-related disorders. In: Agnoli A et al. (eds) Aging brain and ergot alkaloids, Raven, New York, Aging 23: 283–303Google Scholar
  83. Horowski R, Riedel C (1979) Hypothermic action on lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics. Naunyn-Schmiedeberg’s Arch. Pharmacol. 306: 147–151Google Scholar
  84. Horowski R, Runge I (1986) Possible role of gonadal hormones as triggering factors in migraine. Funct. Neurol. 4: 405–414Google Scholar
  85. Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate an ergot derivative in mice. Eur.J. Pharmacol. 36: 373–383PubMedCrossRefGoogle Scholar
  86. Horowski R, Neumann F, Gräf K-J (1975) Influence of apomorphine hydrochloride, dibutyryl-apomorphine and lysenyl on plasma prolactin concentrations in the rat. J Pharm Pharmac 27: 532–534CrossRefGoogle Scholar
  87. Horowski R, Wachtel H (1979) Pharmacological effects of lisuride in rodents mediated by dopaminergic receptors: mechanism of action and influence of chronic treatment with lisuride. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon, Oxford, pp 237–251Google Scholar
  88. Horowski R, von Berswordt-Wallrabe R, Gräf K-J (1976) Role of serotoninergic mechanisms in the regulation of prolactin secretion and possible mechanism of action of ergot derivatives. In: Endroczi E (ed) Cellular and molecular bases of neuroendocrine processes. Akadémiai Kiadó, Budapest, pp 183–195Google Scholar
  89. Horowski R, Wendt H, Gräf K-J (1977) Inhibition of basal and stimulated prolactin secretion by lisuride in humans, Acta Endocrinol. (Kbh.) 87: 234–240Google Scholar
  90. Horowski R, Wachtel H, Dorow R (1986) Dopamine as a deuteragonist in migraine: implications for clinical pharmacology of dopamine agonists. In: Winlow W, Markstein R (eds) The neurobiology of dopamine systems. Manchester University Press, Manchester, pp 415–426Google Scholar
  91. Hümpel M (1983) Pharmacokinetics of lisuride in animals species and humans. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 411–152Google Scholar
  92. Hümpel M, Nieuweboer B, Hasan SH, Wendt H (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effects on plasma prolactin level. Eur J Clin Pharmacol 20: 47–51PubMedCrossRefGoogle Scholar
  93. Itil TM, Herrmann M, Akpinar S (1974) Lisuride hydrogen maleate, a new psychotropic, discovered by quantitative pharmaco-electroencephalogram. Int J Clin Pharmacol 10: 143 (Abstract)Google Scholar
  94. Itil TM, Akpinar S, Herrmann W (1975) Discovery of specific ens effects of lisuride hydrogen maleate — an antimigraine compound. Psychopharmacol Bull 11: 67PubMedGoogle Scholar
  95. Jackson DM, Jenkins OF (1985) Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties. J Neural Transm 62: 219–230PubMedCrossRefGoogle Scholar
  96. Johnson AM, Loew DM, Vigouret JM (1976) Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-dopa. Br J Pharmac 56: 59Google Scholar
  97. Kebabian JW, Kebabian PR (1978) Lergotrile and lisuride: in vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptor. Life Sci 23: 2199–2204PubMedCrossRefGoogle Scholar
  98. Kehr W (1977) Effect of lisuride and other ergot derivatives on mono-aminergic mechanisms in rat brain. Eur J Pharmacol 41: 261–273PubMedCrossRefGoogle Scholar
  99. Kehr W, Speckenbach W (1978) Effect of lisuride and LSD on monoamine synthesis after axotomy or reserpine treatment in rat brain. Naunyn-Schmiedeberg’s Arch Pharmacol 301: 163–169PubMedCrossRefGoogle Scholar
  100. Keller HH, Da Prada M (1979) Central dopamine agonistic activity and microsomal biotransformation of lisuride, lergotrile and bromocriptine. Life Sci 24: 1211–1222PubMedCrossRefGoogle Scholar
  101. Krause W, Nieuweboer B, Ruggieri St, Stocchi F, Suchy I (1988) Pharmacokinetics of lisuride after subcutaneous infusion. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Trans (Suppl) 27: 71–74Google Scholar
  102. Krejci I, Schuh J, Pragerova H, Dlabac A (1985) Lisuride and transdihydrolisuride: differences in action on central dopaminergic function in dependence on the location and the state of receptors. Pol J Pharmacol Pharm 37: 263–272PubMedGoogle Scholar
  103. Ladinsky H (1977) Effect of lisuride on the central cholinergic system. In: Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milan, pp 5–18Google Scholar
  104. Laihinen A, Rinne UK, Sonninen V, Suchy I (1986) Lisuride in comparison to bromocriptine in the treatment of Parkinson’s disease. 26th Scandinavian Congress of Neurology, Uppsala, June 11–14, 1986, Uppsala, J Med Sci Suppl 43: 92Google Scholar
  105. Lamberti P, Bandiera L, De Liso E, Demari M, Fiore P, Iliceto G, Margari L (1986) Rilievi clinici, neuropsicologici e neurofisiologici in Parkinsoniani trattati con lisuride. In: Agnoli A, Battistin L (eds) L.I.M.P.E., Atti della 12. Riunione Morbo di Parkinson: le nuove terapie. Guanella, Rome, pp 197–206Google Scholar
  106. Lees AJ, Bannister R (1981) The use of lisuride in the treatment of multiple system atrophy with autonomie failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiat 44: 347–351PubMedCrossRefGoogle Scholar
  107. Lees AJ, Bannister R (1983) Treatment of the Shy-Drager syndrome with dopaminergic ergots. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 395–405Google Scholar
  108. Lees AJ, Stern GM (1981) Pergolide and lisuride for levodopa-induced oscillations. Lancet II: 577Google Scholar
  109. Leiguarda R, Micheli F, Fernandez Pardal M (1985) Lisuride en la enfermedad de Parkinson. Medicina (Buenos Aires) 45: 29–34Google Scholar
  110. LeWitt PA (1986) Clinical and pharmacological aspects of the antiparkisonian ergolene lisuride. In: Fahn S et al. (eds) Recent developments in Parkinson’s disease. Raven, New York, pp 347–354Google Scholar
  111. LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982) Lisuride versus bromocriptine treatment in Parkinson disease: a double- blind study. Neurology (Ny) 32: 69–72Google Scholar
  112. Lieberman AN, Leibowitz M, Neophytides A, Kupersmith M, Mehl S, Kleinberg D, Serby M, Goldstein M (1979) Pergolide and lisuride for Parkinson’s disease. Lancet II/8152:1129–1130CrossRefGoogle Scholar
  113. Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Pact V, Walker R, Zarosin N, Goodgold A, Goldstein M (1980) The use of two new dopamine agonists: pergolide and lisuride in Parkinson’s disease. In: Rinne UK, Klinger M, Stamm G (eds) Parkinson’s disease - current progress, problems and management. Elsevier/ North Holland Biomedical, Amsterdam, pp 335–356Google Scholar
  114. Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, Kleinberg D (1981a) Lisuride in parkinson disease: Efficacy of lisuride compared to levodopa Neurology (Ny) 31: 961–965Google Scholar
  115. Lieberman AN, Goldstein M, Leibowitz M, Neophytides A, Gopinathan G, Walker R, Pact V (1981b) Lisuride combined with levodopa in advanced parkinson disease. Neurology (Ny) 31: 1466–1469Google Scholar
  116. Lieberman AN, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Goodgold A, Pact V, Walker R (1981 c) Use of lisuride in advanced Parkinson’s disease. N Y State J Medicine Nov 81: 1751–1755Google Scholar
  117. Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E (1983 a) Further studies with lisuride in Parkinson’s disease. Eur Neurol 22: 119–123Google Scholar
  118. Lieberman AN, Goldstein M, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E ( 1983 b) Lisuride in Parkinson’s disease and related disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 419–429Google Scholar
  119. Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Goldstein M (1984) Pergolide and lisuride in advanced Parkinson’s disease. Adv Neurol 40: 503–507PubMedGoogle Scholar
  120. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313: 656–659PubMedCrossRefGoogle Scholar
  121. Loew DM, Van Deusen EB, Meier-Ruge W (1978) Effects on the central nervous system. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, pp 421–531Google Scholar
  122. Loos D, Halbhübner K, Herken H (1977) Lisuride, a potent drug in the treatment of muscular rigidity in rats, Naunyn-Schmiedeberg’s Arch Pharmacol 300: 195–198CrossRefGoogle Scholar
  123. Loos D, Halbhübner K, Kehr W, Herken H (1979) Action of dopamine agonists on parkinson-like muscle rigidity induced by 6-aminonicotinamide. Neuroscience 4: 667–676PubMedCrossRefGoogle Scholar
  124. Lüdecke DK, Herrmann, H-D, Hörmann C, Desaga U, Saeger W (1983) Comparison of effects of dopamine agonists and microsurgery in GH- and PRL-secreting adenomas. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 271–289Google Scholar
  125. Luquin MR, Obeso JA, Martinez-Lage JM, Tresguerres J, Parada J, Nieuweboer B, Dorow R, Horowski R (1986) Parenteral administration of lisuride in Parkinson’s disease. In: Adv Neurol 45: 561–568Google Scholar
  126. MacLeod RM (1977) Influence of dopamine, serotonin, and their antagonists on prolactin secretion. Prog Reprod Biol 2: 54–68Google Scholar
  127. Mannesmann G, Haberey M, Müller B, Goedecke H (1979) Pharmacological characterization of the cardiovascular activity of lisuridhydrogenmaleate. Naunyn- Schmiedeberg’ Arch. Pharmacol. Suppl 308: 72 (abstract)Google Scholar
  128. Marek J, Rezábek K, Srámková (1982) Medikamentöse Behandlung der Hyperprolaktinämie, Akromegalie und Cushing-Krankheit. Ber Ges Inn Med 13: 246–248Google Scholar
  129. Marini JL, Sheard MH (1981) On the specificity of a cat behavior model for the study of hallucinogens. Eur J Pharmacol 70: 479–487PubMedCrossRefGoogle Scholar
  130. Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981) Activity of a non-halluciongenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73: 328–331PubMedCrossRefGoogle Scholar
  131. Martignoni E, Suchy I, Pacchetti C, Sinforiani E, Sandrini G, Nappi G (1986) Lisuride in Parkinson’s disease: naive and long-term treatment. Curr Ther Res 39: 696–708Google Scholar
  132. McCall RB (1982) Neurophysiological effects of hallucinogens on serotonergic neuronal systems. Neurosci Biobehav Rev 6: 509–514PubMedCrossRefGoogle Scholar
  133. McCall RB, Aghajanian GK (1980) Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus. Life Sci 26: 1149–1156PubMedCrossRefGoogle Scholar
  134. McCall RB, Humphrey SJ (1982) Involvement of serotonin in the central regulation of blood pressure: Evidence for a facilitating effect on sympathetic nerve activity. J Pharm Exp Ther 222: 94–102Google Scholar
  135. McDonald RJ, Horowski R (1983) Lisuride in the treatment of parkinsonism. Eur Neurol 22: 240–255PubMedCrossRefGoogle Scholar
  136. McPherson GA, Beart PM (1983) The selectivity of some ergot derivatives for alpha-1-and alpha-2-adrenoceptors of rat cerebral cortex. Eur J Pharmacol 91: 363–369PubMedCrossRefGoogle Scholar
  137. Mereu G, Muntoni F, Collu M, Boi V, Gessa GL (1986) Delayed blockade of dopamine autoreceptors by lisuride In: Biggio S, Spano FP, Toffano G, Gessa GL (eds) Modulation of central and peripheral transmitter function. Liviana/Springer, Berlin Heidelberg New York, pp 597–601Google Scholar
  138. Mereu G, Hu XT, Wang RY, Westfall TC, Gessa GL (1987) Failure of subchronic lisuride to modify A10 dopamine autoreceptors’ sensitivity. Brain Res 408: 210–214PubMedCrossRefGoogle Scholar
  139. Micheli F, Fernandez Pardal MM, Leiguarda RC (1982) Beneficial effects of lisuride in Meige disease. Neurology (Ny) 32: 432–434Google Scholar
  140. Misurek J, Morávek Z, Náhunek K (1978) Lisurid (Lysenyl SPOFA) in the treatment of organic psychosyndrome in involution, Activ Nerv Sup (Praha) 20: 87–88Google Scholar
  141. Munemara M, Eskay RL, Kebabian JW, Long R (1980) Release of alpha-melanocytestimulating hormone from dispersed cells of the intermediate lobe of the rat pituitary gland: involvement of catecholamines and adenosine 3′,5′-monophosphate, Endocrinology 106: 1795–1803CrossRefGoogle Scholar
  142. Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J, Walker R (1982) The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J Neurol Neurosurg Psychiat 45: 261–263PubMedCrossRefGoogle Scholar
  143. Nutt JG, Hammerstad JP, Carter JH, DeGarmo PL (1984) Lisuride treatment of cranial dystonia. 36th Meeting of the American Academy of Neurology, Boston, April 1984Google Scholar
  144. Obeso JA (1984) Untersuchung und Behandlung des Myoclonus. Akt. Neurol. 11: 210–213CrossRefGoogle Scholar
  145. Obeso JA, Rothwell JC, Quinn NP, Lang AE, Thompson C, Marsden CD (1983) Cortical reflex myoclonus responds to intravenous lisuride, Clin Neuropharmacol 6: 231–240PubMedCrossRefGoogle Scholar
  146. Obeso JA, Luquin MR, Martinez Lage JM (1985) Lisuride oral en la enfermedad de Parkinson. Medicina Clinica (Barcelona) 85: 307–312Google Scholar
  147. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
  148. Obeso JA, Horowski R, Marsden CD (eds) (1988) Continuous Dopaminergic Stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27Google Scholar
  149. Otomo E, Hasegawa K, Kuroiwa Y et al. (1981) Effects of lisuride hydrogen maleate on EEG in patients with cerebral vascular impairments and mild senile dementia: multicenter double-blind study, Jpn J Clin Pharmacol Ther 12: 377–396CrossRefGoogle Scholar
  150. Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism, Ann Neurol 9: 48–52PubMedCrossRefGoogle Scholar
  151. Pieri L, Keller HH, Burkard W, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis, Nature 272: 278–280PubMedCrossRefGoogle Scholar
  152. Pieri L, Keller HH, Laurent J-P, Burkard WP, Pieri M, Bonetti EP, Da Prada M (1983) Behavioral, neurochemical, and electrophysiological effects of lisuride and LSD in animals. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 89–96Google Scholar
  153. Podvalovà I, Dlabac A (1972) Lysenyl, a new antiserotonin agent. Res Clin Stud Headache 3: 325–334Google Scholar
  154. Quinn NP (1984) Antiparkinsonian drugs today, Drugs 28: 236–262PubMedCrossRefGoogle Scholar
  155. Quinn N, Marsden CD, Schachter M, Thompson C, Lang AE, Parkes JD (1983) Intravenous lisuride in extrapyramidal disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 383–393Google Scholar
  156. Quinn N, Parkes JD, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedGoogle Scholar
  157. Quinn NP, Lang AE, Sheehy MP, Marsden CD (1985) Lisuride in dystonia. Neurology 35: 766–769PubMedGoogle Scholar
  158. Rabey JM, Treves T, Streifler M, Korczyn AD (1986) Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients. Adv Neurol 45: 569–572Google Scholar
  159. Rabey JM, Streifler M, Treves T, Korczyn AD (1987) Long-term lisuride in Parkinson’s disease. In: Calne DB, Crippa D, Comi G (eds) Int symp parkinsonism and aging, suppl 7. Ital J Neurol Sci Suppl 5: 55Google Scholar
  160. Raffaelli E, Martins OJ, dos Santos P, Dàgua Filho A (1983) Lisuride in cluster headache. Headache 23: 117–121PubMedCrossRefGoogle Scholar
  161. Reynolds GP, Riederer P (1981) The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain. J Neural Transm 51: 107–111PubMedCrossRefGoogle Scholar
  162. Riederer P, Reynolds GP, Danielczyk W, Jellinger K, Seemann D (1983) Desensitization of striatal spiperone-binding sites by dopaminergic agonists in Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 375–381Google Scholar
  163. Rinne UK (1983) New ergot derivatives in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 431–442Google Scholar
  164. Rinne UK (1986) The importance of an early combination of a dopamine agonist and levodopa in the treatment of Parkinson’s disease. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 64–71Google Scholar
  165. Ripka O (1972) Effetti della soministrazione a lungo termine dell’ anti-serotoninico lysenyl nelle cefalee di varia eziologia. Minerva Med 63: 3266–3271PubMedGoogle Scholar
  166. Rogawski MA, Aghajanian GK (1979) Response of central monaminergic neurons to lisuride: comparison with LSD, Life Sci 24: 1289–1298PubMedCrossRefGoogle Scholar
  167. Rosenfeld MR, Makman MH (1981) The interaction of lisuride, an ergot derivative, with serotonergic and dopaminergic receptors in rabbit brain. J Pharmacol Exp Ther 216: 526–531PubMedGoogle Scholar
  168. Rosenfeld MR, Makman MH, Goldstein M (1980) Stimulation of adenylate cyclase in rat striatum by pergolide: influence of GTP. Eur J Pharmacol 68: 65–68PubMedCrossRefGoogle Scholar
  169. Rothwell JC, Obeso JA, Marsden CD (1984) On the significance of giant somatosensory evoked potentials in cortical myoclonus. J Neurol Neurosurg Psychiat 47: 33–42PubMedCrossRefGoogle Scholar
  170. Ruggieri S, Baldassarre M, Del Roscio S, Stocchi F, Palesse N, Martucci N, Agnoli A (1980) Confronto tra l’attività terapeutica della lisuride e della bromocriptina nel morbo di Parkinson. In: Atti della 7. Riunione. LIMPE, Milan 24–25 Oct 1980Google Scholar
  171. Ruggieri S, Stocchi F,Agnoli A (1986) Lisuride infusion pump for Parkinson’s disease, Lancet 11:348–349 (letter)Google Scholar
  172. Ruggieri S, Stocchi F, Antonini A, Bellantuono P, Carta A, Agnoli A (1987) Lisuride infusion in chronically treated fluctuating Parkinson’s disease: effects of continuous dopaminergic stimulation, New Trends Clin Neuropharmacol 1: 55–60Google Scholar
  173. Ruilope L, Garcia-Robles R, Paya C, de Villa LF, Miranda B, Morales JM, Parada J, Sancho J, Rodicio JL (1985) Influence of lisuride, a dopaminergic agonist, on the sexual function of male patients with chronic renal failure. Am J Kidney Dis 5: 182–185Google Scholar
  174. Saiani L, Trabucchi M,Tonon GC, Spano PF (1979) Bromocriptine and lisuride stimulate the accumulation of cyclic AMP in intact slices but not in homogenates of rat neostriatum. Neurosci Lett 14: 31–36PubMedGoogle Scholar
  175. Scaglioni A, Caffarra P, Passeri S, Saginario M (1986) Trattamento a lungo termine con lisuride nel morbo di Parkinson, In: Agnoli A, Battistin L (eds) LIMPE, Atti della 12. Riunione ‘Morbo di Parkinson: le nuove terapie’. Guanella, Rome, pp 207–217Google Scholar
  176. Schachter M, Blackstock J, Dick JPR, George RJD, Marsden CD, Parkes JD (1979) Lisuride in Parkinson’s disease. Lancet 11/8152:1129Google Scholar
  177. Schachter M, Sheehy MP, Parkes JP, Marsden CD (1980) Lisuride in the treatment of parkinsonism, Acta Neurol Scand 32: 382–385Google Scholar
  178. Schmidt-Gollwitzer M, Hardt W, Schmidt-Gollwitzer K, Nevinny-Stickel J (1977) Vergleichsstudie über den Einfluß verschiedener Sexual-steroide, 2-Br-Alpha-Ergokryptin und Lisurid-hydrogenmaleat auf die postpartalen Prolaktin-Serumkonzentrationen und die Laktation. Geburtsh Frauenheilk 37: 500–508PubMedGoogle Scholar
  179. Schneider WHF (1983) Lisuride and female fertility. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 331–335Google Scholar
  180. Scholz A, Horowski R (1987) Effects of the prolactin-lowering agent lisuride (Dopergin R) in early pregnancy. In: Teoh ES, Ratnam SS, Wong PC (eds) Ovulation and early pregnancy. Parthenon, Carnforth, pp 159–162Google Scholar
  181. Schorderet M (1978) Dopamine-mimetic activity of cyclic AMP in isolated retinae of the rabbit. Gerontology 24, Suppl 1: 86–93Google Scholar
  182. Schwibbe M, Becker D, Wuttke W (1983) EEG and psychological effects of lisuride in women with premenstrual tension. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 345–355Google Scholar
  183. Scigliano G, Giovannini P, Grassi MP, Soliveri P, Parati E, Mallucci C, Caraceni T (1982) La lisuride nel trattamento del morbo di Parkinson. In: Atti della 9. Riunione LIMPE, Taormina, 29–30 Oct 1982Google Scholar
  184. Scigliano G, Giovannini P, Grassi MP, Soliveri P, Piccolo I, Lamperti E, Girotti F, Caraceni T (1985) Valutazione dell’efficacia a lungo termine della lisuride nel trattamento del morbo di Parkinson. In: Agnoli A, Battistin L (eds) LIMPE, Atti della 11. Riunione ‘Semeiologia e terapia: delle malattie extrapiramidali le nuove frontiere.’ Guanella, Rome, pp 250–262Google Scholar
  185. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 25: 1144–1148PubMedGoogle Scholar
  186. Silbergeld EK, Hruska RE (1979) Lisuride and LSD: dopaminergic and serotonergic interactions in the „serotonin syndrome“. Psychopharmacology 65: 233–237PubMedCrossRefGoogle Scholar
  187. Somerville BW, Herrmann WM (1978) Migraine prophylaxis with lisuride hydrogen maleate — a double blind study of lisuride versus placebo. Headache 18: 75–79PubMedCrossRefGoogle Scholar
  188. Spano PF, Govoni S, Trabucchi M (1978) Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system In: Adv Biochem Psychopharmacol 19: 155–165Google Scholar
  189. Spano PF, Saiani L, Memo M, Trabucchi M (1980) Interaction of dopaminergic ergot derivatives with cyclic nucleotide system. In: Goldstein M et al. (eds) Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 95–102Google Scholar
  190. Spano PF, Govoni S, Uzumaki H, Bosio A, Memo M, Lucchi L, Carruba M, Trabucchi M (1983) Stimulation of D2-dopamine receptors by dopaminergic ergot alkaloids: studies on the mechanism of action. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 165–117Google Scholar
  191. Stibe CMH, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet 1: 403–406PubMedCrossRefGoogle Scholar
  192. Stocchi F, Ruggieri S, Brughitta G, Agnoli A (1986) Problems in daily motor performances in Parkinson’s disease: the continuous dopaminergic stimulation. J Neural Transm 22: 209–218Google Scholar
  193. Stumpf WE, Detmer WM, Sar M, Horowski R, Dorow R (1985) Autoradiographic studies with [3H] dopamine, and [3H] domperidone in pituitary and brain. In: Macleod RM, Thorner MO, Scapagnini U (eds) Prolactin. Basic and clinical correlates, Liviana, Padova, pp 27–35Google Scholar
  194. Suchy I (1986) Neurotransmitters in intellectual deterioration and dementia in presenium and senium. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 38–43Google Scholar
  195. Suchy I, Horowski R (1984) Use of ergot derivative lisuride in Parkinson’s disease. In: Adv Neurol 40: pp 515–521Google Scholar
  196. Suchy I, Schneider HH, Riederer P, Horowski R (1983) Considerations on the clinical relevance of differences in receptor affinity of various dopaminergic ergot alkaloids. Psychopharmacol. Bull. 19: 743–746Google Scholar
  197. Thorner MO, Vance ML, MacLeod RM (1984) Hyperprolactinaemic infertility: some considerations on medical management. In: Rolland R (ed) Advances in fertility control and the treatment of sterility. MTP Press, Boston, pp 23–25Google Scholar
  198. Tissari AH, Gessa GL (1983) Ergot-induced inhibition of dopamine synthesis in striatal synaptosomes: A D-2 DA receptor-mediated mechanism. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 33–43Google Scholar
  199. Tissari AH, Rossetti ZL, Meloni M, Frau MI, Gessa Gl (1983) Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. Eur J Pharmacol 91: 463–468PubMedCrossRefGoogle Scholar
  200. Ulm G (1983) Experience with lisuride in the treatment of Parkinson’s disease. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists.Google Scholar
  201. Raven, New York, pp 463–472Google Scholar
  202. Ulm G, Suchy I (1986) Drug treatment of Parkinson’s disease with special reference to lisuride. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 55–63Google Scholar
  203. Uzumaki H, Govoni S, Memo M, Carruba MO, Trabucchi M, Spano PF (1982) Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride. Brain Res. 248: 185–187PubMedCrossRefGoogle Scholar
  204. van Dam LJ, Rolland R (1981) Lactation-inhibiting and prolactin-lowering effect of lisuride and bromocriptine: a comparative study. Eur J Obstet Gynec Reprod Biol 12: 323–330CrossRefGoogle Scholar
  205. Venturini PL, Horowski R, Maganza C, Morano S, Pedretti E, Ragni N, Semino F, De Cecco L (1981) Effects of lisuride and bromocriptine on inhibition of lactation and on serum prolactin levels: comparative double-blind study. Eur J Obstet Gynec Reprod Biol 11: 395–400CrossRefGoogle Scholar
  206. Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R (1980) Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest 4: 405–414Google Scholar
  207. Votava Z, Podvalova I, Vojtechovsky M (1966) Unterschiede in der pharmakologischen Wirkung von halluzinogenen und nicht halluzinogenen Lysergsäure-Derivaten (LSD-25, Deseril, Lysenyl, Mesenyl). Arzneim Forsch Drug Res 16: 220–222Google Scholar
  208. Wachtel H (1978) Inhibition of locomotor activity of rats by low doses of different dopamine (DA) receptor agonists. Naunyn-Schmiedeberg’s Arch Pharmacol 302 (Suppl): R 59 (abstract)Google Scholar
  209. Wachtel H, Kehr W, Schlangen M (1986) Involvement of dopamine auto- and postsynaptic receptors in locomotor effects of lisuride in rats after systemic or intracerebral administration. In: van Manen J, Rinne UK (eds) Lisuride: a new dopamine agonist and Parkinson’s disease. Excerpta Medica, Amsterdam, pp 11–23Google Scholar
  210. Wachtel H, Rettig KJ, Löschmann PA (1988) Effect of chronic subcutaneous mini-pump infusion of lisuride upon locomotor activity in rats. In: Obeso JA, Horowski R, Marsden CD (eds) Continuous dopaminergic stimulation in Parkinson’s disease. J Neural Transm (Suppl) 27: 177–183Google Scholar
  211. Walters JR, Baring MD, Lakoski JM (1978) Effects of dopamine agonists on dopaminergic unit activity. In: Usdin E, Kopin IJ, Barchas J (eds) Catecholamines: basic and clinical effects, vol 1. Pergamon, New York, pp 637–639Google Scholar
  212. Walters JR, Baring MD, Lakoski JM (1979) Effects of ergolines on dopaminergic and serotonergic single unit activity In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon, Oxford, pp 207–221Google Scholar
  213. von Werder K, Fahlbusch R, Rjosk H-K (1983) Dopamine agonists and prolactinomas: clinical and therapeutic aspects In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) Lisuride and other dopamine agonists. Raven, New York, pp 255–269Google Scholar
  214. White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions, Pharmacol Biochem Behav 24:365–379PubMedCrossRefGoogle Scholar
  215. White FJ, Wang RY (1982a)Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions Science 216: 535–537PubMedCrossRefGoogle Scholar
  216. White FJ, Appel JB (1982 b) The role of dopamine and serotonin in the discriminative stimulus effects of lisuride, J Pharmacol Exp Ther 221: 421–427Google Scholar
  217. White FJ, Wang RY (1983) Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat. Neuropharmacology 22: 669–676PubMedCrossRefGoogle Scholar
  218. Winkelmann W, Allolio B, Deuß U, Heesen D, Kaulen D, Wilcke O (1983) Medikamentöse Langzeittherapie bei Patienten mit Prolaktin-produzierenden Hypophysentumoren. Akt Endokr Stoffw 4: 163–168Google Scholar
  219. Zikán V, Semonsky M (1968) Mutterkorn-Alkaloide: 31. Mitt.: Ein Beitrag zur Herstellung von N-(D-6-Methyl-8-isoergolenyl)-N’N’-diäthylharnstoff. Pharmazie 23: 147–148Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • G. Gopinathan
  • R. Horowski
  • I. H. Suchy

There are no affiliations available

Personalised recommendations